Business Wire

Automotive and Transportation Leader Pamela Fletcher Joins Sion Power as Chief Executive Officer

13.8.2024 16:00:00 EEST | Business Wire | Press release

Share

Sion Power Corporation, a leading technology developer of next-generation batteries for electric vehicles (EV), announced today that Pamela Fletcher has joined the company as its new Chief Executive Officer. A renowned veteran of the automotive industry, Fletcher brings a proven track record of electric vehicle development and deployment, which she will leverage to accelerate the company’s transition to commercialization. She succeeds Tracy Kelley, who will transition to President and Chief Science Officer of Sion Power and continue development of world class battery technology breakthroughs.

Most recently, Fletcher served as the Senior Vice President, Chief Sustainability Officer, at Delta Air Lines where she led the airline’s sustainability and innovation efforts in service of the company’s Net Zero future. In this role she set a strategy to net zero emissions by 2050 and activated initiatives across the organization to achieve short to long-term goals, an industry first. Before her tenure at Delta Air Lines, Fletcher spent more than 15 years at General Motors where she held instrumental leadership positions, including Vice President of Global Innovation and Vice President of Electric Vehicles. She led the teams that delivered the electric Chevrolet Bolt and Chevrolet Volt to market, as well as the first true, hands-free driver assistance technology—Super Cruise.

“Again and again, Pam has been at the forefront of the automotive industry, leading award-winning product, technology, and new businesses teams. She has a passion for innovation and a track record of scaling high-growth business ventures, disrupting established industries, and attracting new customers. She has the skillset and passion to lead the commercialization of Sion Power’s breakthrough Licerion® battery technology and we’re thrilled for this next chapter,” said Stefan Jacoby, Chair, Sion Board of Directors.

“Sion Power is poised to be the first company to commercialize a lithium-metal anode through its Licerion® technology for large volume EV applications, thus disrupting the global battery industry,” said Fletcher, CEO, Sion Power. “Commercialization means more affordable electric vehicles for consumers more quickly, bolstering adoption and ultimately helping us get closer to a zero emissions world. I am honored to join this incredible company and I want to thank Tracy Kelley for his leadership to this pivotal point and all he will continue to do for our team.”

Sion Power has developed lithium-based batteries for over three decades. Over the past eight years, batteries based on their proprietary and patented technology have been its focus. This disruptive energy storage system is projected to deliver twice the specific energy when compared to today's conventional lithium-ion batteries. To learn more, visit sionpower.com.

About Sion Power

Sion Power is moving the rechargeable battery industry forward with its Licerion® technology. Licerion® is an advanced approach to lithium-metal batteries containing twice the energy in the same size and weight battery, compared to a traditional lithium-ion battery. At up to 500 Wh/kg, Licerion® batteries are produced at scale in large-format cells. As a result, Licerion® batteries have the potential to significantly enhance the performance of commercial and consumer electric vehicles. Visit Sion Power at sionpower.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240813464461/en/

Contacts

Press.Release@sionpower.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 10:00:00 EET | Press release

Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe

Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 08:00:00 EET | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 08:00:00 EET | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 27-31 in Denver, Colorado. Twenty-two abstracts will be presented, including late-breaking data and three oral presentations spanning Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare. “Galderma is on a path towards becoming the undisputed dermatology powerhouse and, as such, aims to set the bar for scientific excellence in the field. The range of data we are presenting at AAD shows the strength of our commitment to this across every part of our portfolio. Patients deserve sophisticated, effective solutions that meet their diverse and evolving needs, and our science is built to deliver exactly that.” BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D AND CORPORATE DEVELOPMENT GALDERMA Therapeutic Dermatology: Latest updat

Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 08:00:00 EET | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri

HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 05:36:00 EET | Press release

HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye